Pricing Log in Create free account
Friday 6 November 2026 Export HAE’s income statement to Excel — free account

Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.

Revenue
+9.30%
EPS
+25.9%
Free cash flow
+20.4%
Total debt
+21.0%

Quarter to September 2026, against a year earlier

121.10 3.01 −2.43%
Market cap
$5.7B
P/E
54.5×
Fwd P/E
30.2×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 1.89%

Capital & Financial Ratios $m

Size
Market Cap 5,650.00
Revenue ttm 1,382.46
Net income ttm 103.91
Free cash flow ttm 344.93
Net debt Q 853.41
Valuation
P/E 54.48 (above 35: high)
Forward P/E 30.20
Price / sales 4.05
Forward P/S Powerpack
Price / FCF 18.11
Price / book 6.24 (above 6: high)
Financial health
Current ratio Q 2.84 (at or above 1.5: strong)
Debt / equity Q 1.24
Interest coverage Q 6.13
Growth
Revenue growth Q +9.30% (above 0%: growing)
Operating income growth Q +28.43% (above 0%: growing)
EPS, this year +7.47%
EPS, next year A +13.66%
Revenue, next year A +6.22%
EPS, past 5 yrs +5.75%
EPS, next 5 yrs A +11.98%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.7×, against a ten-year median of 3.9×; over the ten years it ranged from 1.8× in 2016 to 7.4× in 2021.
P/E against its own 10 years 54.57%
10-year low 10-year high
P/S against its own 10 years 70.52%
10-year low 10-year high
P/B against its own 10 years 73.08%
10-year low 10-year high
EV/Sales against its own 10 years 74.26%
10-year low 10-year high
EV/FCF against its own 10 years 13.02%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 179 307 245 261
Receivables 207 203 217 225
Inventory 317 365 306 305
Other — — — —
769 935 835 856
2024 2025 2026 Q'26
Payables 73 67 51 72
ST’ Debt — — — —
Other 136 148 158 165
300 578 283 301

Compound Annual Growth %

10y 5y 3y
Sales 3.91% 8.91% 4.51%
Cash Flow 9.18% 21.93% 2.40%
Earnings 0.00% 4.13% (5.53%)
Book Value 0.99% 1.71% (0.89%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate 1.07 Actual 1.14

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 1.12 1.27 Beat by 0.15
Q3 FY26 1.27 1.31 Beat by 0.04
Q4 FY26 1.28 1.29 Beat by 0.01
Q1 FY27 1.07 1.14 Beat by 0.07
Q2 FY27 1.30 — Reports 5 November 2026

EPS $

Jun Sep Dec Mar Year
’26 0.72 1.00 — — —
’26 0.70 0.81 0.95 (0.44) 2.05
’25 0.74 0.66 0.74 1.17 3.31
’24 0.80 0.48 0.61 0.40 2.29
’23 0.38 0.64 0.64 0.57 2.24
’22 (0.09) 0.29 0.45 0.19 0.84
’21 0.21 0.94 0.62 (0.22) 1.55
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 339 358 — — —
’26 321 327 339 346 1,334
’25 336 346 349 331 1,361
’24 311 318 336 343 1,309
’23 261 297 305 304 1,169
’22 229 240 260 265 993
’21 196 209 240 225 870
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 52 128 — — —
’26 17 111 94 71 293
’25 (27) 49 44 117 182
’24 19 99 (1) 64 182
’23 42 87 64 80 273
’22 (2) 43 62 68 172
’21 12 29 66 2 109
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 45 128 — — —
’26 14 106 88 54 262
’25 (13) 40 35 103 166
’24 12 91 (15) 58 145
’23 (3) 58 48 (20) 83
’22 (15) 23 36 34 78
’21 5 21 57 (9) 74
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Sep ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 886 904 968 988 870 993 1,169 1,309 1,361 1,334 1,382 +4.7% 1,417 1,495 1,599 +6.2%
Gross margin, % 42.71 45.57 43.15 49.02 45.70 50.90 52.63 52.83 55.04 59.04 59.63 +16.3 pt
EBT (27) 60 74 87 73 64 141 152 212 128 142 n/m
EBT margin, % (3.10) 6.60 7.61 8.82 8.38 6.41 12.10 11.60 15.58 9.60 10.27 +12.7 pt
Net income (26) 46 55 77 79 43 115 118 168 97 104 n/m
Per share, $
Per share, $ Revenue 17.20 17.13 18.78 19.50 17.17 19.46 23.01 25.82 27.04 28.28 30.38 +5.7%
Earnings (0.51) 0.85 1.07 1.51 1.57 0.84 2.24 2.32 3.33 2.05 2.26 n/m
Cash flow 3.10 4.18 3.09 3.12 2.15 3.37 5.38 3.58 3.61 6.22 7.58 +8.0%
Capex (1.42) (1.37) (2.25) (0.63) (0.69) (1.85) (3.74) (0.72) (0.32) (0.67) 0.00 (8.1%)
Free cash flow 1.68 2.81 0.84 2.49 1.45 1.52 1.64 2.87 3.29 5.55 7.58 +14.2%
Book value 14.35 14.26 12.96 11.58 14.43 14.68 16.11 18.93 16.31 16.88 19.75 +1.8%
Shares, m 52 53 52 51 51 51 51 51 50 47 46 (1.0%)
Valuation, ×
Valuation, × P/E 0.00 83.91 85.48 66.00 71.16 75.26 36.78 37.03 19.03 27.76 54.48 50.2
P/S 2.36 4.21 4.78 5.11 6.46 3.25 3.60 3.28 2.35 1.99 4.05 3.7
P/B 2.83 5.06 6.93 8.60 7.69 4.31 5.14 4.48 3.90 3.34 6.24 5.2
EV/Sales 2.49 4.08 4.94 5.28 7.04 3.55 4.00 3.76 2.80 2.72 4.67 4.1
EV/FCF 25.51 24.85 110.78 41.35 83.24 45.35 56.06 33.82 23.01 13.88 20.87 45.8
Cash, $m
Cash, $m Operating cash flow 160 220 159 158 109 172 273 182 182 293 345 +7.0%
Capex (73) (72) (116) (32) (35) (94) (190) (36) (16) (31) (36) (9.0%)
Free cash flow 86 148 43 126 74 78 83 145 166 262 345 +13.1%
Balance, $m
Balance, $m Working capital 299 136 340 329 440 314 518 469 357 552 555 +7.1%
Net debt 114 (121) 153 168 498 300 470 619 614 974 853 +26.9%
Shareholders’ equity 740 752 668 587 732 749 818 960 821 796 898 +0.8%
Returns, %
Returns, % ROA (2.05) 3.68 4.38 6.02 5.15 2.36 6.08 5.69 7.22 4.02 4.28 +6.1 pt
ROIC (1.42) 5.56 6.36 8.55 4.56 4.81 7.57 6.53 9.66 5.53 6.31 +7.0 pt
ROE (3.60) 6.11 7.75 12.20 12.05 5.86 14.72 13.22 18.83 12.03 11.89 +15.6 pt
People
People Employees 3,107 3,136 3,216 3,004 2,708 2,821 3,034 3,657 3,023 3,009 — (0.4%)
Revenue/emp, $m 0.29 0.29 0.30 0.33 0.32 0.35 0.39 0.36 0.45 0.44 — +5.0%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Haemonetics Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 9.9× — +0.52% (above 0%: growing) n/m +8.07% (above 0%: growing) 50.06% (7.57%) Compare
BIO Bio-Rad Laboratories, Inc. $9.9B 9.7× 44.7× +0.52% (above 0%: growing) n/m +8.07% (above 0%: growing) 50.06% (7.57%) Compare
BRKR Bruker Corporation $8.9B — (loss-making) — (loss-making) +1.57% (above 0%: growing) n/m +278.74% (above 0%: growing) 49.12% (10.41%) Compare
TXG 10x Genomics $7.6B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%) Compare
HAE Haemonetics Corporation $5.7B 54.5× 30.2× +9.30% (above 0%: growing) +25.93% (above 0%: growing) +20.37% (above 0%: growing) 61.75% 21.00%
LIVN LivaNova PLC $5.0B 25.6× 19.8× +9.88% (above 0%: growing) +27.41% (above 0%: growing) −30.95% (below 0%: shrinking) 67.41% 7.22% Compare
ITGR Integer Holdings Corporation $4.3B 42.2× 38.9× −3.86% (below 0%: shrinking) −61.04% (below 0%: shrinking) −65.19% (below 0%: shrinking) 22.59% 6.27% Compare
IRTC iRhythm Holdings, Inc. $4.3B — (loss-making) — (loss-making) +14.88% (above 0%: growing) n/m −157.58% (below 0%: shrinking) 74.23% (14.69%) Compare
AXGN AxoGen, Inc. $2.9B — (loss-making) — (loss-making) +26.22% (above 0%: growing) +163.16% (above 0%: growing) +994.99% (above 0%: growing) 74.81% 1.26% Compare
Median of peers $6.3B 17.8× 38.9× +1.05% +27.41% +1.73% 58.74% (7.57%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 9 June 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 12.04m 8.12m 48.23
2025 10.72m 1.35m 62.60
2024 11.55m 10.18m 84.55
2023 10.69m 18.08m 81.97
2022 8.70m (2.35m) 63.25

Ownership

Directors and executive officers, together 2.07% of Common Stock
BlackRock, Inc.50 Hudson YardsNew York, New York 13.33% of Common Stock
Neuberger Berman Group LLCNeuberger Berman Investment Advisers LLC1290 Avenue of the AmericasNew York, NY 7.77% of Common Stock
AQR Capital Management LLCOne Greenwich Plaza, Suite 6.96% of Common Stock
Vanguard Portfolio Management LLC100 Vanguard Blvd.Malvern, Pennsylvania 5.72% of Common Stock
Vanguard Capital Management LLC100 Vanguard Blvd.Malvern, Pennsylvania 5.38% of Common Stock
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Haemonetics Corporation (HAE) Latest News

6 Nov

Impact 3 · · GuruFocus.com

5 Nov

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript

3 Nov

Impact 3 · · Insider Monkey

28 Oct

Impact 4 · · Insider Monkey

27 Oct

Impact 3 · · Zacks

21 Oct

Impact 3 · · StockStory

19 Oct

Impact 4 · · PR Newswire
Impact 3 · · CNW Group

16 Oct

Impact 4 · · Zacks

15 Oct

Impact 4 · · Zacks

9 Oct

Impact 4 · · Zacks
Impact 4 · · Simply Wall St.

8 Oct

Impact 4 · · Stocktwits
Impact 4 · · Proactive Investors
Impact 4 · · TIKR
Impact 4 · · Investing.com
Impact 4 · · Proactive Investors

22 Sep

Impact 4 · · Simply Wall St.

15 Sep

Impact 3 ·

20 Aug

Impact 3 ·

15 Aug

Impact 4 ·
Impact 3 ·
Impact 3 ·

14 Aug

Impact 4 ·

13 Aug

Impact 3 · · The Motley Fool transcript

11 Aug

Impact 3 ·

9 Aug

Impact 3 ·

8 Aug

Impact 3 · · MarketBeat transcript

6 Aug

Impact 3 · · Moby transcript

HAE metrics, ten years each

stockrow.com/HAE · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com